Clinical trials: Skin Toxicity
Breast Cancer, Drug-Related Side Effects and Adverse Reactions
Telenursing for the Early Detection and Management of Side Effects Associated With Cyclin-Dependent Kinase Inhibitors in Breast Cancer Patients
This study is a multicenter randomized controlled trial designed to evaluate the effectiveness of a structured telenursing intervention in patients with breast cancer receiving cyclin-dependent kinase (CDK) inhibitor therapy.
- Conditions
- Breast Cancer, Drug-Related Side Effects and Adverse Reactions, Chemotherapy Toxicity, Treatment Adherence
- Trial name
- NCT07524829
- Testing
- Structured Telenursing Follow-up, Standard Nursing Care
- Where
- Italy
- Volunteers
- 124 people
- Sponsor
- Azienda Sanitaria Locale di Asti
Breast Neoplasms, Cardiac Event
Clinical Study of Xinmailong Injection on Reducing Cardiovascular Toxicity in Adjuvant Chemotherapy in Breast Cancer
Totally 60 subjects will be included in the study. The present study was aimed to observe and evaluate the effect of Xinmailong injection on reducing cardiovascular toxicity associated with adjuvant chemotherapy after breast…
- Conditions
- Breast Neoplasms, Cardiac Event, Chemotherapeutic Toxicity
- Trial name
- NCT03785704
- Testing
- Xinmailong Injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College
Rash Due to Epidermal Growth Factor Receptor Inhibitors
A Study to Examine the Effect of Reconval K1 Cream to Prevent Skin Toxicity From EGFRI
Vitamin K1 cream may prevent papulopustular rash induced by EGFRI given to metastatic colorectal cancer patients. This study will prospectively accrue metastatic colorectal patients receiving EGFRI and treat with reconval cream…
- Trial name
- EGFRI (NCT01763307)
- Testing
- RECONVAL CREAM
- Volunteers
- 18 people
- Sponsor
- Hadassah Medical Organization
Breast Cancer, Breast Carcinoma
Evaluation of Ocoxin®-Viusid® in Breast Cancer
The purpose is to determine the efficacy of the nutritional supplement Ocoxin-Viusid oral solution (OV) in the reduction of acute toxicity of Chemotherapy (CT) treatment with patients with breast carcinoma.
- Conditions
- Breast Cancer, Breast Carcinoma, Adriamycin Toxicity, Cyclosporine Toxicity
- Trial name
- NCT03576521
- Testing
- CT + Ocoxin-Viusid
- Where
- Cuba
- Volunteers
- 120 people
- Sponsor
- Catalysis SL
Breast Cancer, Chemotherapeutic Agent Toxicity
S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, II, or IIIA Breast Cancer Undergoing Chemo
RATIONALE: Acetyl-L-carnitine may prevent or lessen neuropathy caused by chemotherapy. It is not yet known whether acetyl-L-carnitine is more effective than a placebo in preventing neuropathy caused by chemotherapy.
- Conditions
- Breast Cancer, Chemotherapeutic Agent Toxicity, Fatigue, Neuropathy
- Trial name
- NCT00775645
- Testing
- acetyl-L-carnitine hydrochloride
- Where
- 295 sites in United States
- Volunteers
- 437 people
- Sponsor
- SWOG Cancer Research Network
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ
Pyridoxine and Topical Urea/Lactic Acid-Based Cream in Preventing Hand-Foot Syndrome in Patients Receiving Capecitabine for Breast Cancer or Other Cancer
RATIONALE: Pyridoxine (vitamin B6) and topical urea/lactic acid-based cream may prevent or lessen hand-foot syndrome caused by chemotherapy.
- Conditions
- Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00296036
- Testing
- pyridoxine hydrochloride, urea/lactic acid-based topical cream
- Where
- 231 sites in United States
- Volunteers
- 137 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Stage III Melanoma
Interferon Toxicities in Melanoma Treatment
The primary objective of this study is to quantify and compare the prevalence of adverse events (AEs) in patients with stage III melanoma before and after initiation of interferon (IFN) therapy in a real-world setting.
- Trial name
- ITMT (NCT02794636)
- Volunteers
- 436 people
- Sponsor
- Bristol-Myers Squibb
Breast Cancer
Effects of Short-term Fasting on Tolerance to Chemotherapy
The purpose of this study is to determine the effect of short-term fasting on tolerance to adjuvant chemotherapy in breast cancer patients
- Trial name
- NCT01304251
- Testing
- Short-term fasting, Healthy nutrition
- Where
- Netherlands
- Volunteers
- 13 people
- Sponsor
- Leiden University Medical Center
Colorectal Cancer Metastatic, Skin Toxicity
Panitumumab Skin Toxicity Prevention Trial
Background and rationale: EGFR represents the main and more studied signal activation pathway in the development of colorectal carcinoma.
- Trial name
- PaSTo (NCT03167268)
- Testing
- Lycopene
- Where
- Italy
- Volunteers
- 28 people
- Sponsor
- Ospedale San Carlo Borromeo
Triple Negative Breast Cancer (TNBC)
Evaluating Ovarian Toxicity Outcomes Following Immunotherapy in Patients With Triple-Negative Breast Cancer (TNBC)
This study aims to collect information about the effects of chemotherapy combined with immunotherapy (immune checkpoint inhibitors) for early-stage triple-negative breast cancer (TNBC) on ovarian function and fertility.
- Trial name
- FERTILE (NCT07527819)
- Where
- 9 sites in Australia
- Volunteers
- 75 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Metastatic Breast Cancer
Study Evaluating Impact of IL-7 on CD4 Lymphopenia, Risks of Severe Haematological Toxicity and Tumor Progression in Metastatic Breast Cancer Patients
The purpose of the study is to evaluate the impact of an immunotherapy by IL-7 on CD4 lymphopenia, risks of severe haematological toxicity and tumor progression in metastatic breast cancer patients.
- Trial name
- NCT01368107
- Testing
- interleukin 7
- Where
- 3 sites in France
- Volunteers
- 24 people
- Sponsor
- Centre Leon Berard
Breast Cancer, Cardiac Toxicity
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, fluorouracil, epirubicin hydrochloride, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Conditions
- Breast Cancer, Cardiac Toxicity, Perioperative/Postoperative Complications
- Trial name
- NCT01093235
- Testing
- bevacizumab, cyclophosphamide, docetaxel
- Where
- United Kingdom
- Volunteers
- 800 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Colorectal Cancer, Breast Cancer
Effect of Genetic Polymorphism on Capecitabine-Induced Toxicity in Egyptian Cancer Patients
The goal of this observational study is to study the effect of a single nucleotide polymorphism in the CES1 gene (rs2244613) on capecitabine-induced toxicity in Egyptian cancer patients.
- Trial name
- NCT06765252
- Testing
- Capecitabine-based chemotherapy
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Ain Shams University
Melanoma
Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for Melanoma Intracranial and Extracranial Metastases
The goal of this clinical research study is to find the recommended dose level and recommended number of injections of the study agent DNX-2401 that can be given to patients with metastatic melanoma that have intracranial and/or…
- Trial name
- NCT07444606
- Testing
- DNX-2401
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Colorectal Cancer
Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer
RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Conditions
- Breast Cancer, Colorectal Cancer, Pain
- Trial name
- NCT00305643
- Testing
- Capecitabine, Celecoxib, Radiation Therapy
- Where
- 14 sites in United States, Puerto Rico
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Identifying Ideal Reimbursement "Dose" to Reduce Clinical Trial-related Financial Toxicity
The goal of this clinical trial is to explore the feasibility and preliminary impact of a pilot financial reimbursement intervention for women with breast cancer living in the Deep South who are eligible for a clinical trial.
- Trial name
- NCT05871125
- Testing
- Reimbursement
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Alabama at Birmingham
Skin Toxicity in Patients on Checkpoint Inhibitors
"Evaluation of a Non-Pharmacological Skin Care Intervention for the Prevention and Treatment of Skin Toxicities Caused by Immunotherapy in Cancer Patients"
Due to recent approvals, a significant number of adult cancer patients are undergoing treatment with checkpoint inhibitor antibodies.
- Trial name
- NCT07337486
- Testing
- Shea Butter and Niacinamide, Argan Oil and Coconut Butter
- Where
- Spain
- Volunteers
- 130 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Breast Neoplasms, Quality of Life (QOL)
A Study of Treatment-Related Toxicities and Quality of Life After Local Therapy in Chinese Breast Cancer Patients
This study, called PERSEVERE, examines how local treatment for early breast cancer affects people's health and daily lives over time.
- Conditions
- Breast Neoplasms, Quality of Life (QOL), Toxicities, Breast Diseases
- Trial name
- PERSEVERE (NCT07010939)
- Testing
- blood sampling
- Where
- 3 sites in China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- FangYi
Breast Cancer, Breast Tumors
Use of Metformin to Reduce Cardiac Toxicity in Breast Cancer
The goal of this study is to determine if co-administration of metformin and doxorubicin in breast cancer patients receiving neoadjuvant or adjuvant therapy will reduce the number of patients who develop a significant change in…
- Trial name
- NCT02472353
- Testing
- Metformin, Doxorubicin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Avera McKennan Hospital & University Health Center
Therapeutic Patient Education, Immune Checkpoint Inhibitors
Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology
The aim of this therapeutic education program is to reduce the apparition of immune-related Adverse Event with patients treated with ICI
- Conditions
- Therapeutic Patient Education, Immune Checkpoint Inhibitors, Melanoma, Advanced Non-small Cell Lung Cancer
- Trial name
- EDHITO (NCT03948724)
- Testing
- Therapeutic education program, Usual Information
- Where
- 9 sites in France
- Volunteers
- 412 people
- Sponsor
- Institut Cancerologie de l'Ouest